The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...

GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...

North America severe asthma market is set for growth, driven by high asthma prevalence, increased awareness, and advanced treatment options for severe cases. Ankush Nikam Future Market Insights, Inc.

GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...

If approved, depemokimab would be a companion and successor to Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma and various other indications that made sales of ...

The antibody is a follow-up to the company's once-monthly IL-5 inhibitor Nucala (mepolizumab), which has been on the market since 2015. Nucala is approved for four indications, namely severe ...

Across China’s west, the Communist Party is placing children in boarding schools to assimilate a generation of Tibetans into the national mainstream and mold them into loyal citizens. By Chris ...

After Donald Trump suggested he might take over Greenland by force, the consensus among the island’s population appears to be bewilderment and anxiety. By Jeffrey Gettleman and Maya Tekeli The ...